Zevra Therapeutics
ZVRA
148 hedge funds and large institutions have $385M invested in Zevra Therapeutics in 2026 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 53 increasing their positions, 53 reducing their positions, and 25 closing their positions.
13% more capital invested
Capital invested by funds: $342M → $385M (+$42.8M)
2.61% more ownership
Funds ownership: 67.76% → 70.37% (+2.6%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 53
6% less funds holding
Funds holding: 158 → 148 (-10)
28% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 25
32% less call options, than puts
Call options by funds: $14.2M | Put options by funds: $20.7M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$10.8M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$10.4M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$7.38M |
| 4 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$6.76M |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$4.38M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$4.9M |
| 2 |
Jane Street
New York
|
-$3.09M |
| 3 |
CM
Caption Management
Oklahoma City,
Oklahoma
|
-$2.57M |
| 4 |
Tudor Investment Corp
Stamford,
Connecticut
|
-$2.24M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$2.07M |
ZVRA Hedge Fund Activity: Q1 2026 in Review
148 of the 8,187 institutional investors tracked by Wall St. Rank reported a position in Zevra Therapeutics (ZVRA) for Q1 2026, worth a combined $385M — up 13% from $342M a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of ZVRA and 18 opened new positions — a net loss of 7 holders — while 53 trimmed existing stakes and 53 added.
The largest buyer was AIGH Capital Management, opening a new position worth an estimated $10.8M. The largest seller was Millennium Management, cutting an estimated $4.9M.
- 148 institutional investors held Zevra Therapeutics (ZVRA) as of Q1 2026, down from 158 in Q4 2025.
- Funds reported $385M of Zevra Therapeutics stock for Q1 2026, up 13% quarter-over-quarter.
- 18 funds opened new Zevra Therapeutics positions in Q1 2026 and 25 closed out, a net change of -7 holders.
- The largest Zevra Therapeutics buyer in Q1 2026 was AIGH Capital Management, an estimated $10.8M added.
- The largest Zevra Therapeutics seller in Q1 2026 was Millennium Management, an estimated $4.9M sold.
Based on aggregated 13F filings for Q1 2026.